Kerry Clem
Corporate Officer/Principal presso ACORDA THERAPEUTICS, INC.
Patrimonio netto: 6 658 $ in data 31/03/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Ronald Cohen | M | 68 | 29 anni | |
John Kelley | M | 70 | 16 anni | |
Sandra Panem | M | 77 | 26 anni | |
Peder K. Jensen | M | 69 | 13 anni | |
John Varian | M | 64 | 2 anni | |
Thomas Burns | M | 50 | 1 anni | |
Neil S. Belloff | M | 64 | 3 anni | |
Michael Gesser | M | 61 | 3 anni | |
Denise J. Duca | F | - | 22 anni | |
Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 anni |
Sofia Ali | F | - | - | |
Susan Way | F | - | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Shawn O'Brien | M | - |
Solstice Neurosciences, Inc.
Solstice Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Solstice Neurosciences, Inc. was a specialty biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty biopharmaceutical products. The company was founded in 2004 and is headquartered in Malvern, PA. | 3 anni |
Robert Morales | M | 57 | 7 anni | |
Jeff Randall | M | 80 | 17 anni | |
Lauren Sabella | F | 63 | 12 anni | |
Adrian L. Rabinowicz | M | - | 6 anni | |
David Stout | M | 69 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 anni |
Steven M. Rauscher | M | 70 | 15 anni | |
Ian Smith | M | 58 | 12 anni | |
Jane Wasman | F | 67 | 15 anni | |
Barry Greene | M | 60 | 14 anni | |
Catherine D. Strader | M | 70 | 4 anni | |
Pablo Cagnoni | M | 60 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 2 anni |
Jennifer Burstein | F | 52 | 9 anni | |
Elizabeth Keating | F | - | - | |
Brian W. Hutchinson | M | - | 5 anni | |
Thomas C. Aquilina | M | - | - | |
Peter Carbone | M | - | - | |
Todd F. Baumgartner | M | - | 5 anni | |
Rebecca R. Levine | F | - | 5 anni | |
Steven Fruchtman | M | 73 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 2 anni |
Michael Samar | M | 51 | 3 anni | |
Erin Campany | F | 57 | 4 anni | |
Andrew Mayer | M | - | - | |
Enrique Carrazana | M | 62 | 5 anni | |
Herbert Raymond Henney | M | - | 9 anni | |
Andrew Hindman | M | 51 | 5 anni | |
Soon H. Lee | M | - | - | |
Ruhi Khan | F | - | 5 anni | |
Anthony Caggiano | M | 54 | 16 anni | |
Eric Siegel | M | 60 |
Solstice Neurosciences, Inc.
Solstice Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Solstice Neurosciences, Inc. was a specialty biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty biopharmaceutical products. The company was founded in 2004 and is headquartered in Malvern, PA. | 2 anni |
Benedict Osorio | M | 67 | 2 anni | |
Thomas C. Wessel | M | 68 | 3 anni | |
Martin Freed | M | 63 | 1 anni | |
Richard Batycky | M | 56 | - | |
Wise Young | M | 74 | 16 anni | |
Michael Rogers | M | 64 | 3 anni | |
Luke Seikkula | M | 60 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 anni |
Burkhard Blank | M | 69 | 5 anni | |
Christopher Kenney | M | - | 3 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 51 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Kerry Clem
- Contatti personali